Shocking $45M AI Breakthrough: Is This the End of Traditional Drug Discovery?

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- In a significant development for the pharmaceutical industry, ChemLex, a next-generation AI-for-science company, announced the establishment of its global headquarters and a self-driving laboratory in Singapore. This move coincides with the completion of a USD 45 million funding round led by Granite Asia.

Founded in 2022, ChemLex specializes in developing AI technologies that expedite chemical discovery, dramatically shortening the time it takes for new drugs to reach the market. Within just three and a half years, the company has expanded its client base to include over 70 customers worldwide, notably encompassing six of the world’s top ten pharmaceutical companies. This rapid growth aligns with a broader trend in the industry, where analysts project that the AI-powered drug discovery market will explode from USD 3.6 billion in 2024 to nearly USD 50 billion by 2034.

At the heart of ChemLex's operations is a 24/7 autonomous chemistry system that not only accelerates chemical discovery but also enhances cost-efficiency and sustainability compared to traditional laboratory methods. This system is powered by an innovative AI-driven, fully automated synthesis line capable of conducting experiments independently, capturing real-time data, and transforming the usually fragmented chemical discovery process into a streamlined workflow.

The recent funding will be instrumental in expanding ChemLex's workforce in Singapore as the company aims to hire more hardware and software engineers, along with chemists. This expansion is vital for supporting a broader array of pharmaceutical and materials science projects.

Sean Lin, Founder and CEO of ChemLex: "We're building an R&D engine that compresses months of synthesis and optimization into weeks or even days, transforming both the speed and certainty of discovery. Singapore strengthens this effort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now."

Yinghui Kuang, a Partner at Granite Asia, emphasized the transformative potential of AI in chemistry, stating,

"AI-enabled chemistry is creating one of the most important industrial transitions of the decade, and ChemLex sits in that sweet spot, turning that shift into a business advantage with a platform that can accelerate molecule design and manufacturing at scale."

Kuang noted that ChemLex's innovations could reshape supply chains, shorten development timelines, and unlock new economic value. Singapore provides a robust foundation for such growth.

In addition to its infrastructural advancements, ChemLex has signed a memorandum of understanding with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development. This collaboration aims to accelerate the discovery of next-generation small molecule drugs through advanced automation.

Prof. Damian O'Connell of the Experimental Drug Development Centre: "We first met ChemLex in 2023, and since then we've seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis. As ChemLex's first Singapore partner, we are thrilled to expand our collaboration through the MOU."

He added that the partnership reinforces their shared vision of accelerating drug development through cutting-edge technology to deliver safer and more effective therapies to patients faster. By combining EDDC's drug development expertise with ChemLex's automation and AI, they aim to shorten timelines and reduce costs, ultimately delivering innovative treatments that improve lives both in Singapore and globally.

These initiatives align seamlessly with the Singapore Economic Development Board's (EDB) commitment to fostering a resilient and innovation-ready life sciences ecosystem. Goh Wan Yee, Senior Vice President and Head of Healthcare at the EDB, stated,

"ChemLex's decision to anchor its global R&D headquarters and AI laboratory in Singapore reflects how companies can leverage the confluence of our strengths in deep tech and biomedical sciences ecosystem to launch breakthrough innovations."

The EDB looks forward to supporting similar partners like ChemLex in accelerating scientific discoveries that ultimately benefit patients on a global scale.

The establishment of ChemLex's headquarters in Singapore not only highlights the city-state's growing prominence as a hub for biotechnology and pharmaceuticals but also underscores the increasing integration of AI technologies in various sectors. As the global demand for innovative drug discovery solutions continues to rise, ChemLex may play a pivotal role in shaping the future of healthcare.